Hoth Therapeutics Files S-1 for Potential Stock Offering
Ticker: HOTH · Form: S-1 · Filed: Apr 11, 2024 · CIK: 1711786
| Field | Detail |
|---|---|
| Company | Hoth Therapeutics, Inc. (HOTH) |
| Form Type | S-1 |
| Filed Date | Apr 11, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001, $9.49 million, $1.40 |
| Sentiment | neutral |
Sentiment: neutral
Topics: s-1, registration-statement, pharmaceuticals
TL;DR
Hoth Therapeutics just filed an S-1, get ready for a potential stock sale.
AI Summary
Hoth Therapeutics, Inc. filed an S-1 registration statement on April 11, 2024, indicating plans to offer securities. The company, incorporated in Nevada with its principal executive offices in New York, operates in the Pharmaceutical Preparations sector. This filing is part of their process to potentially raise capital through the sale of stock.
Why It Matters
This S-1 filing signals Hoth Therapeutics' intention to access public markets, which could lead to new funding for its pharmaceutical development or other corporate initiatives.
Risk Assessment
Risk Level: medium — S-1 filings often precede stock offerings, which carry inherent market risks and dilution potential for existing shareholders.
Key Numbers
- 333-278620 — SEC File Number (Identifies this specific registration statement with the SEC.)
- 24838712 — Film Number (Internal SEC processing number for the filing.)
Key Players & Entities
- Hoth Therapeutics, Inc. (company) — Registrant
- April 11, 2024 (date) — Filing Date
- Nevada (jurisdiction) — State of Incorporation
- New York (location) — Principal Executive Offices
- 2834 (sic_code) — Standard Industrial Classification
- Robb Knie (person) — Chief Executive Officer
- Richard A. Friedman (person) — Legal Counsel
- Emily A. Mastoloni (person) — Legal Counsel
- Sheppard, Mullin, Richter & Hampton LLP (company) — Legal Counsel Firm
FAQ
What is the purpose of this S-1 filing by Hoth Therapeutics, Inc.?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public, indicating Hoth Therapeutics' intent to potentially raise capital.
When was this S-1 filing submitted to the SEC?
The S-1 filing was submitted to the SEC on April 11, 2024.
In which state was Hoth Therapeutics, Inc. incorporated?
Hoth Therapeutics, Inc. was incorporated in Nevada.
Who is listed as the Chief Executive Officer of Hoth Therapeutics, Inc.?
Robb Knie is listed as the Chief Executive Officer of Hoth Therapeutics, Inc.
What is the primary business sector for Hoth Therapeutics, Inc. according to the filing?
Hoth Therapeutics, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,405 words · 18 min read · ~15 pages · Grade level 16.6 · Accepted 2024-04-11 16:15:49
Key Financial Figures
- $0.001 — 0,000 shares of common stock, par value $0.001 per share (the “Common Stock&rdqu
- $9.49 million — n gross proceeds to us of approximately $9.49 million. However, we cannot predict when and in
- $1.40 — ported on The Nasdaq Capital Market was $1.40 per share. There is no established publ
Filing Documents
- ea0203284-s1_hoththerape.htm (S-1) — 737KB
- ea020328401ex5-1_hothther.htm (EX-5.1) — 14KB
- ea020328401ex23-1_hothther.htm (EX-23.1) — 2KB
- ea020328401ex-fee_hothther.htm (EX-FILING FEES) — 22KB
- image_001.jpg (GRAPHIC) — 136KB
- ex5-1_001.jpg (GRAPHIC) — 9KB
- 0001213900-24-032207.txt ( ) — 976KB
Use of Proceeds
Use of Proceeds 36 Dividend Policy 36 Determination of Offering Price 36
Business
Business 37 Management 47 Executive and Director Compensation 52 Certain Relationships and Related Person Transactions 56
Security Ownership of Beneficial Owners and Management
Security Ownership of Beneficial Owners and Management 57
Description of Capital Stock
Description of Capital Stock 58 Selling Stockholders 61 Plan of Distribution 62 Legal Matters 64 Experts 64 Where You Can Find More Information 64 Incorporation of Documents by Reference 65 i ABOUT THIS PROSPECTUS This prospectus relates to the resale by the Selling Stockholders identified in this prospectus under the caption “Selling Stockholders,” from time to time, of up to an aggregate of 5,030,000 shares of Common Stock. We are not selling any shares of Common Stock under this prospectus, and we will not receive any proceeds from the sale of shares of Common Stock offered hereby by the Selling Stockholders, although we may receive cash from the exercise of the Warrants. You should rely only on the information provided in this prospectus, including any information incorporated by reference. We have not authorized anyone to provide you with any other information and we take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give you. The information contained in this prospectus speaks only as of the date set forth on the cover page and may not reflect subsequent changes in our business, financial condition, results of operations and prospects. We are not, and the Selling Stockholders are not, making offers to sell these securities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such an offer or solicitation. You should read this prospectus, including any information incorporated by reference, in its entirety before making an investment decision. ii CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING This prospectus contains forward-looking
Use of proceeds
Use of proceeds We will not receive a